Bluebird Could Find US Tailwind For Zynteglo After ICER Report

 
• By Alaric DeArment

The cost-effectiveness watchdog now assumes an upfront $2.1m payment instead of five annual payments. The company switched gears to the US after the TDT gene therapy stumbled in Europe.

ICER released a revised version of its report on bluebird bio's Zynteglo • Source: Shutterstock

More from Gene Therapies

More from Advanced Therapies